Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

BACKGROUND: Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2. We report exploratory analyses, including the long-term outcome of candi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Br J Cancer
Hoofdauteurs: Hodgson, Darren R., Dougherty, Brian A., Lai, Zhongwu, Fielding, Anitra, Grinsted, Lynda, Spencer, Stuart, O’Connor, Mark J., Ho, Tony W., Robertson, Jane D., Lanchbury, Jerry S., Timms, Kirsten M., Gutin, Alexander, Orr, Maria, Jones, Helen, Gilks, Blake, Womack, Chris, Gourley, Charlie, Ledermann, Jonathan, Barrett, J. Carl
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group UK 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6265286/
https://ncbi.nlm.nih.gov/pubmed/30353044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0274-8
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items